By week 12, 27.7% of Crohn’s patients taking AbbVie’s SKYRIZI had little to no gut inflammation, vs. 10.2% on…
Google News · 2026-10-14 03:15 · 资讯
By week 12, 27.7% of Crohn’s patients taking AbbVie’s SKYRIZI had little to no gut inflammation, vs. 10.2% on placebo.
By week 12, 27.7% of Crohn’s patients taking AbbVie’s SKYRIZI had little to no gut inflammation, vs. 10.2% on placebo.
话题：#By week 12, 27.7% of Crohn’s patients
墨子AI
